Company profile for Pieris Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the...
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
255 State Street, 9th floor Boston, MA 02109
Telephone
Telephone
+1 (857) 246-8998
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/12/13/2997010/0/en/Palvella-Therapeutics-Announces-Closing-of-Merger-with-Pieris-Pharmaceuticals-and-Concurrent-Private-Placement-of-78-9-Million.html

GLOBENEWSWIRE
13 Dec 2024

https://www.accesswire.com/847235/pieris-pharmaceuticals-announces-strategy-to-maximize-partnered-milestone-and-royalty-potential

ACCESSWIRE
27 Mar 2024
Pieris lays off 70% of staff after AstraZeneca axes collab
Pieris lays off 70% of staff after AstraZeneca axes collab

19 Jul 2023

// Max Bayer FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/astrazeneca-bails-pieris-asthma-asset-thrusting-biotech-restructuring-70-layoffs

Max Bayer FIERCE BIOTECH
19 Jul 2023

https://www.clinicaltrialsarena.com/news/pieris-review-asthma-drug/

CLINICAL TRIALS ARENA
05 May 2023
Pieris puts phase 2 cancer drug out on chopping block
Pieris puts phase 2 cancer drug out on chopping block

05 Aug 2022

// Gabrielle Masson FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/too-many-cooks-kitchen-pieris-culls-phase-2-cancer-drug-focus-astrazeneca-asthma-collab

Gabrielle Masson FIERCEBIOTECH
05 Aug 2022

https://www.clinicaltrialsarena.com/news/pieris-dosing-gastric-cancer-trial/

CLINICALTRIALSARENA
17 Jan 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty